Group 1 - The article promotes a weekly newsletter focused on stocks in the biotech, pharma, and healthcare industries, highlighting key trends and catalysts that influence market valuations [1] - Edmund Ingham, a biotech consultant with over 5 years of experience, leads the Haggerston BioHealth investing group, which caters to both novice and experienced investors [1] - The investing group provides insights such as buy and sell ratings, product sales forecasts for major pharmaceutical companies, and detailed financial analyses [1]

Core Insights - Beam Therapeutics (BEAM) is focused on developing gene therapy candidates for hematology and genetic diseases using proprietary base-editing technology, which minimizes errors by targeting a single base in the genome without causing double-stranded breaks in DNA [1] Pipeline Development - Risto-cel (formerly BEAM-101) is an ex vivo therapy in phase I/II BEACON study for sickle cell disease (SCD), showing mean HbF induction of over 60% and HbS reduction to below 40% in treated patients [2] - Initial safety and efficacy data for risto-cel indicated a significant increase in fetal hemoglobin and a reduction in sickle hemoglobin, leading to FDA orphan drug and Regenerative Medicine Advanced Therapy designations [3] - The company has initiated a phase I study for BEAM-103, an experimental anti-CD117 monoclonal antibody for SCD [4] - Beam is also developing BEAM-301 and BEAM-302 for glycogen storage disease type 1a (GSD1a) and alpha-1 antitrypsin deficiency (AATD), respectively, with updates expected in early 2026 [5] Competitive Landscape - Beam Therapeutics faces competition from other companies utilizing CRISPR/Cas9 technology, such as CRISPR Therapeutics, which has launched the first CRISPR/Cas9-based therapy, Casgevy, for SCD and beta-thalassemia [8] - Intellia Therapeutics is advancing in vivo candidates for hereditary angioedema and transthyretin amyloidosis, with pivotal studies expected to yield data by mid-2026 [9][11] Financial Performance - Over the past six months, Beam Therapeutics shares have increased by 58.7%, outperforming the industry average of 25.1% [12] - The company's shares are trading at a price/book ratio of 2.92, below the industry average of 3.65 and its five-year mean of 3.03 [13] - The Zacks Consensus Estimate for BEAM's loss per share for 2025 has widened from $4.23 to $4.44, with 2026 estimates also increasing from $4.21 to $4.60 [14]

Key Points Vertex could have several catalysts in 2026, helping it set a strong foundation for the future. DexCom is expanding its addressable market in order to help deal with some current challenges. 10 stocks we like better than Vertex Pharmaceuticals › Broader equities posted yet another strong performance in 2025. Will they keep the momentum going in 2026? That's hard to say. Several factors could affect the economy and the stock market next year. This year turned out to be great despite som ...

Contrarius Investment Management, an investment management company, released its third-quarter investor letter for the “Contrarius Global Equity Fund”. A copy of the letter can be downloaded here. The fund’s investor class returned 30.9% in the September quarter compared to 7.3% for the benchmark MSCI World Index, including reinvested net income, and 5.5% for the Average Global Equity Fund. The fund’s investment philosophy is independent of benchmark considerations, so the portfolios typically deviate from ...

Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity Strategy” investor letter for the third quarter of 2025. A copy of the letter can be downloaded here. The portfolio underperformed in the quarter due to stock selection. The composite returned 5.02%, net of fees, compared to 7.62% for the MSCI AC World Net Index. In addition, please check the fund’s top five holdings to know its best picks in 2025. In its third-quarter 2025 investor letter, Ha ...

Amazon - Amazon has deployed over 1 million robots in its warehouses, projected to save up to $4 billion annually in fulfillment costs, with expectations of significantly lifting operating margins for the retail segment by 2030 [1] - The company is investing heavily in AI, with planned capital expenditures projected at $125 billion in 2025, focusing on custom silicon chips to enhance performance and reduce costs compared to competitors [2] - Amazon's advertising segment is the fastest-growing, with annualized revenue expected to exceed $60 billion in 2025, potentially approaching $100 billion annually in the coming years [3] - Amazon Web Services (AWS) remains the primary profit engine, accounting for approximately 30% of the global cloud infrastructure market [4] - In Q3 2025, Amazon reported revenue of $180.2 billion, a 13% year-over-year increase, with net income rising 38% to $21.2 billion [7] Vertex Pharmaceuticals - Vertex Pharmaceuticals has a trailing-10-year return of around 90%, driven by its cystic fibrosis drug franchise and expansion into the rare disease market [8] - The company is diversifying its portfolio with late-stage clinical programs targeting kidney disease, pain management, and type 1 diabetes, supported by a solid balance sheet and substantial free cash flow [9] - Vertex is launching Casgevy, a gene-editing therapy for sickle cell disease, and Journavx, a non-opioid medicine for pain management, with significant market interest and regulatory approvals [10][11] - The company reported revenue of over $3 billion in Q3 2025, an 11% increase from the previous year, and is positioned for significant growth through innovation and diversification [14] TJX Companies - TJX Companies has seen a nearly 150% increase in stock value over the last five years, attributed to its effective off-price retail model [15] - The company plans to expand its store footprint to 7,000 globally, enhancing its physical presence in existing and new markets [16] - TJX's business model encourages frequent shopper visits due to its ever-changing inventory and unique product offerings, appealing to cost-conscious consumers [17] - In Q3 2026, TJX reported earnings per share of $1.28 on $15.1 billion in revenue, reflecting year-over-year increases of 12% and 7% respectively [19]

Core Viewpoint - Moderna has transitioned from a clinical-stage biotech to a profitable commercial-stage company due to its coronavirus vaccine, but recent declines in vaccine sales and underperformance of its RSV vaccine raise concerns about its growth potential [1][2] Group 1: Moderna's Current Situation - Moderna's stock has seen a decline in vaccine sales, and its RSV vaccine has not met growth expectations [2] - Despite challenges, Moderna has made progress in cost-cutting and is focusing on promising programs, leading to a stock increase of over 30% in the past month [2] - The company aims for cash breakeven by 2028 and the launch of new products, which may not appeal to cautious investors [5] Group 2: Vertex Pharmaceuticals Overview - Vertex Pharmaceuticals is highlighted as a better investment option for both cautious and aggressive investors due to its strong earnings growth in cystic fibrosis treatment [6] - Vertex's CFTR modulators, Trikafta and Alyftrek, treat nearly 95% of cystic fibrosis patients, with ongoing development for remaining patients [7] - Vertex's revenue increased by 11% to over $3 billion in the latest quarter, driven by its CF products [8] Group 3: New Product Approvals and Pipeline - Vertex has expanded its product line with approvals for Casgevy and Journavx, which could significantly boost revenue in the coming years [9] - Journavx addresses a critical need for effective non-opioid pain management, with over 300,000 prescriptions filled since its launch [9] Group 4: Financial Performance and Valuation - Vertex's stock has increased nearly 100% over the past five years and about 15% this year, indicating strong long-term and short-term performance [11] - The current valuation of Vertex is 25 times forward earnings estimates, a reasonable price given its market leadership and expanding product portfolio [11] - Vertex's financial strength and diverse product offerings position it well for future growth, making it a more attractive investment compared to Moderna [12]

There are some risks to consider before jumping on the bandwagon.Once again, the technology sector drove much of the market's gains this year. The healthcare industry, on the other hand, has been a bit of a laggard.However, there have been notable standouts among medically focused stocks. The list of strong performers includes CRISPR Therapeutics (CRSP +0.44%), a biotech company, and HCA Healthcare (HCA +0.03%), a leading hospital chain. They have outperformed the S&P 500, (^GSPC +0.32%) rising by 44% and 5 ...

Core Viewpoint - CRISPR Therapeutics has experienced significant stock volatility, with a notable decline of over 60% from its 2021 peak, despite the recent approval and commercialization of its first gene editing therapy, Casgevy, for blood disorders [2][10]. Group 1: Product Approval and Technology - Casgevy is the first CRISPR-based product approved for treating blood disorders, specifically sickle cell disease and beta thalassemia [4][7]. - The CRISPR technology utilized by the company involves precise DNA editing, which may provide a functional cure for the diseases it targets, potentially allowing patients to remain symptom-free over time [5][4]. Group 2: Financial Performance and Revenue Generation - Despite the approval of Casgevy, it has not yet generated significant revenue for CRISPR Therapeutics, as the treatment process is complex and requires establishing authorized treatment centers [7][8]. - Vertex Pharmaceuticals, a partner in the Casgevy project, anticipates that the product could generate over $100 million in revenue for the full year of 2025, but CRISPR Therapeutics will only retain 40% of the profits from this product [8][7]. Group 3: Market Sentiment and Future Outlook - The stock performance of CRISPR Therapeutics has been negatively impacted by the time it takes for revenue growth to materialize post-approval, leading some investors to view the company as "yesterday's news" [10][2]. - The company has a pipeline of other candidates based on CRISPR technology, which may also take time to deliver revenue growth and profit [9][10].

Core Viewpoint - Healthcare stocks have underperformed compared to broader equities this year, but there are still attractive investment opportunities in the sector for long-term investors [1] Group 1: CRISPR Therapeutics - CRISPR Therapeutics is a gene-editing company with potential catalysts for stock price growth, particularly with its therapy Casgevy for sickle cell disease and beta-thalassemia [4] - The company has been enhancing third-party coverage and establishing treatment centers for Casgevy, which is expected to see significant growth next year [5] - CRISPR is also developing SRSD107, a potential anticoagulant with promising phase 1 results, and CTX112, which targets various cancers and autoimmune disorders, both of which could contribute to stock price increases [6][8] Group 2: Vertex Pharmaceuticals - Vertex Pharmaceuticals has faced challenges this year, primarily due to its reliance on its cystic fibrosis (CF) treatments, but these continue to generate steady revenue [10] - In Q3, Vertex reported an 11% year-over-year revenue increase to $3.08 billion and a 4.7% increase in net earnings per share to $4.20, indicating strong performance in its core area [11] - The company is advancing new therapies, including zimislecel for Type 1 diabetes and candidates targeting kidney diseases, with regulatory submissions planned for next year [13][14]